Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 694 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
17 Results
Pivotal Response Treatment for Children With Autism Spectrum Disorders (PRT)
- Child Development & Autism
- Genetics
- Mental Health & Behavioral Research
- Gender:All Genders
- Age:4 years - 35 years
Comparing F4C to Batterer Intervention
- Child Development & Autism
- Children's Health
- Mental Health & Behavioral Research
- Gender:Male only
- Age:18 years and older
TMS to Treat Core Social Deficits in Autism Spectrum Disorder
- Child Development & Autism
- Mental Health & Behavioral Research
- Gender:All Genders
- Age:18 years - 40 years
Comprehensive Therapy for Irritability in Teenagers with Autism Study
- Child Development & Autism
- Children's Health
- Mental Health & Behavioral Research
- Gender:All Genders
- Age:11 years - 16 years
CBT for Anxiety in Children With Autism
- Child Development & Autism
- Children's Health
- Mental Health & Behavioral Research
- Gender:All Genders
- Age:8 years - 14 years
PRISM: Patient Experiences with PET Imaging in Prostate Cancer
- Prostate Cancer
Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO
- Diabetes
- Brain, Spinal Cord & Nervous System
- Gender:All Genders
- Age:18 years - 65 years
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Thyroid and Other Endocrine Cancers
- Pancreatic Cancer
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- Stomach and Esophagus
- Prostate Cancer
- Bladder Cancer
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient
- Phase 1 Cancers
1-10 of 17 Results